Vibativ® (telavancin) – Product Discontinuation

- The FDA announced the discontinuation of Vibativ (telavancin) 250 mg vials due to business reasons.
    - The discontinuation is not due to product quality, safety or efficacy concerns.
    - Per Theravance Biopharma, the majority of Vibativ use is with the 750 mg vial.
    - The Vibativ 750 mg/vial injection is still available.

- Vibativ is indicated for the treatment of adult patients with complicated skin and skin structure infections caused by susceptible isolates of certain Gram-positive microorganisms, and for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia, caused by susceptible isolates of *Staphylococcus aureus* (both methicillin-susceptible and -resistant isolates).

- Other currently available antibiotics within the same lipoglycopeptide class include Dalvance® (dalbavancin) and Orbactiv® (oritavancin). Refer to their respective drug labels for specific indication information.